Neoadjuvant Immunochemotherapy in PD-L1-negative LACC
Status:
RECRUITING
Trial end date:
2030-12-12
Target enrollment:
Participant gender:
Summary
This is a multicenter, prospective, single-arm, phase 2 clinical trial designed to evaluate the therapeutic efficacy of the NACI (neoadjuvant chemotherapy plus Camrelizumab) for PD-L1-negative locally advanced cervical cancer.
Phase:
PHASE2
Details
Lead Sponsor:
Tongji Hospital
Collaborators:
Anhui Provincial Cancer Hospital Beijing Friendship Hospital Cancer Hospital of Guangxi Medical University Gansu Provincial Maternal and Child Health Care Hospital Qilu Hospital of Shandong University Shengjing Hospital Sichuan Cancer Hospital and Research Institute Southwest Hospital, China Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University Tianjin Medical University General Hospital West China Second University Hospital Women's Hospital School Of Medicine Zhejiang University Xiangya Hospital of Central South University Zhejiang Cancer Hospital